This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Trump Accelerates Psychedelic Drug Reviews
Regulatory regulatory change

Trump Accelerates Psychedelic Drug Reviews

Analysis based on 29 articles · First reported Apr 18, 2026 · Last updated Apr 25, 2026

Sentiment
60
Attention
6
Articles
29
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market for psychedelic-based therapies is expected to see significant growth due to the accelerated review process by the United States — Food and Drug Administration and increased funding from the United States — United States Department of Health and Human Services. This regulatory shift, driven by Donald Trump's executive order, will likely attract more investment into companies like DemeRx and Atai Life Sciences, and potentially lead to new approved treatments for mental health conditions, creating new revenue streams for pharmaceutical and biotechnology firms.

Pharmaceuticals Biotechnology Healthcare
Event Summary

President Donald Trump signed an executive order directing the United States — Food and Drug Administration and other federal agencies to accelerate reviews and ease restrictions on psychedelic drugs, including ibogaine, psilocybin, and methylone. This move aims to speed up access to potential treatments for conditions like PTSD, severe depression, and opioid addiction. The United States — Food and Drug Administration will issue national priority vouchers for three psychedelics, significantly shortening their review timelines, and has authorized initial testing for a drug related to ibogaine by DemeRx. The United States — United States Department of Health and Human Services is also directed to allocate at least $50 million to states advancing psychedelic drug programs. This initiative, influenced by figures like Robert F. Kennedy Jr. and Joe Rogan, marks a significant shift in federal policy towards psychedelics, despite past safety concerns highlighted by entities like the United States — National Institutes of Health and the Multidisciplinary Association for Psychedelic Studies.

Entities Involved
per
Marcus Luttrell
Marcus Luttrell, a former Navy SEAL, endorsed ibogaine's benefits to Donald Trump, sharing his personal positive experience with the drug.
Importance 30.0 Sentiment 20.0
per
Atai Life Sciences
Atai Life Sciences is a company studying MDMA and other psychedelic compounds, benefiting from investments from figures like Peter Thiel as the regulatory environment shifts.
Importance 30.0 Sentiment 30.0
per
John Krystal
John Krystal, a Yale School of Medicine psychiatrist, emphasizes the need for careful management of psychedelics as a serious medical procedure due to inherent risks.
Importance 30.0 Sentiment 0.0
ngo
Americans for Ibogaine
Americans for Ibogaine, co-founded by Rick Perry, advocates for the use of ibogaine and has influenced research funding in Texas.
Importance 25.0 Sentiment 20.0
priv
Beond Ibogaine
Beond Ibogaine operates a clinic in Cancun, Mexico, treating thousands with ibogaine and providing free treatment to veterans, demonstrating the existing market for the drug.
Importance 25.0 Sentiment 20.0
per
Calley Means
Calley Means, a senior health adviser and former Robert F. Kennedy Jr. campaign staffer, is a proponent of psychedelics and plans to invest in companies developing these drugs.
Importance 25.0 Sentiment 20.0
ngo
Multidisciplinary Association for Psychedelic Studies
The Multidisciplinary Association for Psychedelic Studies, a nonprofit, has conducted early studies on ibogaine and notes its link to over 30 deaths, providing important safety context.
Importance 25.0 Sentiment 20.0
per
Ismail Lourido Ali
Ismail Lourido Ali, co-executive director of the Multidisciplinary Association for Psychedelic Studies, believes Donald Trump's order will encourage more states to fund psychedelic research.
Importance 20.0 Sentiment 15.0
per
Tom Feegel
Tom Feegel of Beond Ibogaine noted that while Donald Trump's order won't immediately lead to insurance coverage, it federally acknowledges ibogaine, shifting its perception.
Importance 20.0 Sentiment 15.0
per
Brad Burge
Brad Burge notes that the increased visibility and demand for psychedelics have led to the expansion of retreat services and improved safety measures.
Importance 20.0 Sentiment 0.0
per
Joshua White
Joshua White, founder of the Fireside Project, expresses concern about the lack of regulation in the psychedelic retreat industry, fearing a 'race to the bottom' regarding quality of care.
Importance 20.0 Sentiment 0.0
per
Amy McGuire
Amy McGuire, a biomedical ethicist, advises potential attendees of psychedelic retreats to conduct thorough research due to the lack of industry-wide standards and oversight.
Importance 20.0 Sentiment 0.0
per
Jeffrey Lieberman
Jeffrey Lieberman, a Columbia University psychiatrist, warns about the risks of discontinuing medications like antidepressants before psychedelic experiences, emphasizing the need for professional supervision.
Importance 20.0 Sentiment 0.0
per
Frederick Barrett
Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, noted the difficulty of studying ibogaine due to its cardiotoxicity and expressed hope for objective research.
Importance 15.0 Sentiment 10.0
ngo
Fireside Project
The Fireside Project runs a hotline for people experiencing distress during psychedelic trips, highlighting the need for support in an unregulated industry.
Importance 10.0 Sentiment 0.0
+ 18 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.